



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/533,416	04/17/2006	Sherman Fong	P1995R1	8968
9157	7590	05/08/2008	EXAMINER	
GENENTECH, INC.			WOODWARD, CHERIE MICHELLE	
1 DNA WAY			ART UNIT	PAPER NUMBER
SOUTH SAN FRANCISCO, CA 94080			1647	
MAIL DATE		DELIVERY MODE		
05/08/2008		PAPER		

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No. 10/533,416	Applicant(s) FONG ET AL.
	Examiner CHERIE M. WOODWARD	Art Unit 1647

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If no period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED. (35 U.S.C. § 133).

Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1) Responsive to communication(s) filed on 27 March 2008.

2a) This action is FINAL. 2b) This action is non-final.

3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4) Claim(s) 7-9 is/are pending in the application.

4a) Of the above claim(s) 8 and 9 is/are withdrawn from consideration.

5) Claim(s) _____ is/are allowed.

6) Claim(s) 7 is/are rejected.

7) Claim(s) _____ is/are objected to.

8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

9) The specification is objected to by the Examiner.

10) The drawing(s) filed on 4/17/2006 is/are: a) accepted or b) objected to by the Examiner.
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) Notice of References Cited (PTO-892)
 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)
 3) Information Disclosure Statement(s) (PTO-166a)
 Paper No(s)/Mail Date 9/5/07, 6/13/07, 08/24/05

4) Interview Summary (PTO-413)
 Paper No(s)/Mail Date _____
 5) Notice of Informal Patent Application
 6) Other: _____

DETAILED ACTION

Election/Restrictions

1. Applicant's election with traverse of Groups 2879 and 2878 (recited as Groups 1479-2956 drawn to SEQ ID NOs: 1399 and 1400) in the reply filed on 3/27/2008 is acknowledged. The traversal is on the ground(s) that claims 7, 8, and 9 can be searched together. This is not found persuasive because the instant case is a national stage filing under 35 USC 371 and the examiner previously found a lack of unity in the case (see Requirement for Restriction/Election mailed 2/28/2008) (see also MPEP 1850). The requirement is still deemed proper and is therefore made FINAL.

2. Although Applicant was instructed to identify ONE SEQ ID NO, corresponding to the correlated group, the examiner will rejoin Groups 2879 and 2878, because Group 2879 is directed to claim 7 as it reads on SEQ ID NO: 1400 and Group 2878 is directed to claim 7 as it reads on SEQ ID NO: 1399. Applicant has pointed out that SEQ ID NO: 1399 is the nucleic acid encoding the polypeptide of SEQ ID NO: 1400.

3. Claims 7, 8, and 9 are pending. Claims 8 and 9 are withdrawn from consideration. Claim 7 is under examination as being drawn to SEQ ID NOs: 1399 and 1400.

Information Disclosure Statements

4. The information disclosure statements (IDS) submitted on 8/24/2005, 6/13/2007, and 9/5/2007 have been considered. Signed copies are attached hereto.

Claim Rejections - 35 USC § 102

5. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

6. Claim 7 is rejected under 35 U.S.C. 102(b) as being anticipated by Chang, US Patent 5,741,772, 21 April 1998.

Claim 7 recites an isolated polypeptide having at least 80% amino acid sequence identity to a polypeptide of SEQ ID NO: 1400. The '772 patent teaches an isolated polypeptide having 100% amino acid sequence identity to SEQ ID NO: 1400 (see SEQ ID NO: 13; Figure 6 oncostatin, and column 4,

Art Unit: 1647

brief description of the drawings for Figure 6) (see also, sequence search results in SCORE) (compare instant claim 7).

RESULT 1
US-08-792-019B-13
Sequence 13, Application US/08792019B
Patent No. 5741772
GENERAL INFORMATION:
APPLICANT: CHANG, MING-SHI
TITLE OF INVENTION: THE NEUROTROPHIC FACTOR NNT-1
NUMBER OF SEQUENCES: 16
CORRESPONDENCE ADDRESS:
ADDRESSEE: AMGEN INC.
STREET: 1840 DEHAVILLAND DRIVE
CITY: THOUSAND OAKS
STATE: CA
COUNTRY: USA
ZIP: 91320
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/792,019B
FILING DATE: 03-FEB-1997
CLASSIFICATION: 514
ATTORNEY/AGENT INFORMATION:
NAME: COOK, ROBERT R.
REGISTRATION NUMBER: 31,602
REFERENCE/DOCKET NUMBER: A-442
INFORMATION FOR SEQ ID NO: 13:
SEQUENCE CHARACTERISTICS:
LENGTH: 252 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: protein
FEATURE:
NAME/KEY: Protein
LOCATION: 1..227
FEATURE:
NAME/KEY: Region
LOCATION: -25..0
US-08-792-019B-13

Query Match 100.0%; Score 1306; DB 1; Length 252;
Best Local Similarity 100.0%; Pred. No. 9.7e-139;
Matches 252; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MGVLLTQRTTILSLVLAELLFPPMSAAGMSAAGSCSKEYRVLLLGQLQQTDLMDTSRLLDPEYI 60

Art Unit: 1647

Db	1 MGVLLTQRTLSSLVLALLFPPSMASMAIGSCSKERYRVLLGQLQKQTDLMQDTSRLLDPYI	60
QY	61 RIQGLDVPKLRREHCRERPGAFPSEETLRLGLRRGFLQTLNATLGCVLHRLADLEQRLPKA	120
Db	61 RIQGLDVPKLRREHCRERPGAFPSEETLRLGLRRGFLQTLNATLGCVLHRLADLEQRLPKA	120
QY	121 QDLERSGLNIEDLEKLQMARPNILGLRNNIYCHMAQLLDNSDTAEPTKAGRGAQPPTPTF	180
Db	121 QDLERSGLNIEDLEKLQMARPNILGLRNNIYCHMAQLLDNSDTAEPTKAGRGAQPPTPTF	180
QY	181 ASCDAFQRKLEGCRFLHGYHRFMHGVGRVFSKNGESPNIRSRRHSPHQALRKGVRRTRPSRK	240
Db	181 ASCDAFQRKLEGCRFLHGYHRFMHGVGRVFSKNGESPNIRSRRHSPHQALRKGVRRTRPSRK	240
QY	241 GKRLMTRGQLPR	252
Db	241 GKRLMTRGQLPR	252

Conclusion

NO CLAIM IS ALLOWED.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to CHERIE M. WOODWARD whose telephone number is (571)272-3329. The examiner can normally be reached on Monday - Friday 9:00am-5:30pm (EST).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Manjunath N. Rao can be reached on (571) 272-0939. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Cherie M. Woodward/
Examiner, Art Unit 1647